Sermorelin (5mg)

Description

Sermorelin Peptide Overview

Sermorelin is a 29-amino-acid synthetic peptide and the shortest peptide known to potentially activate growth hormone-releasing hormone (GHRH) receptors. It is an analog of GHRH (1-29) amide and mimics the natural hormone’s structure and function. Researchers have studied Sermorelin extensively in models of growth hormone deficiency.

The peptide binds to GHRH receptors on the pituitary gland and may stimulate the release of human growth hormone (hGH). This action can increase levels of insulin-like growth factor-1 (IGF-1), which plays a key role in growth hormone-mediated anabolic effects. Sermorelin has a short half-life of approximately 11–12 minutes. Its receptor specificity suggests it may not significantly alter other hormones such as prolactin, insulin, cortisol, glucose, or thyroid hormones.

Chemical Composition of Sermorelin Peptide

• Molecular Formula: C149H246N44O42S

• Molecular Weight: 3357.93 g/mol

• Other Names: GRF 1-29

Mechanism of Action and Receptor Interaction

Sermorelin interacts with GHRH receptors to trigger complex cellular signaling pathways. Upon binding, it may alter receptor conformation and activate adenylate cyclase, increasing cyclic AMP (cAMP) levels. Higher cAMP activates protein kinase A (PKA), which phosphorylates target proteins and stimulates hGH secretion from pituitary somatotroph cells. The released growth hormone then promotes IGF-1 synthesis, supporting anabolic and growth-related functions.

Growth and Anabolic Effects

Studies in models of idiopathic growth hormone deficiency reported that consistent Sermorelin exposure increased growth velocity and height within 12 months. Benefits were sustained for an average of 36 months in long-term observations.

Preclinical and clinical studies suggest that Sermorelin can increase growth hormone levels by 82–107% and elevate IGF-1 levels by about 28%. Researchers observed a lean body mass gain of approximately 1.26 kg (2.78 lbs) without significant fat increase. Skin thickness also improved, indicating potential anabolic and tissue-enhancing effects.

Effects in Lipodystrophy

A controlled clinical study with 31 HIV-positive subjects evaluated Sermorelin’s impact on lipodystrophy. Participants receiving the peptide for 12 weeks showed significantly increased growth hormone and IGF-1 levels. This led to enhanced lean body mass and a reduction in abdominal visceral fat and the trunk-to-limb fat ratio, while glucose and insulin levels remained stable.

Research and Usage

Sermorelin remains a focus of research for growth hormone deficiency, anabolic support, and fat distribution management. Its selective receptor action, combined with a short half-life, makes it a promising candidate for studies in hormonal regulation and metabolic health. You may also be interested in our related research peptides, including GHRP 2 Peptide, Fragment 176-191, Follistatin 344, LL-37 Peptide, Melanotan 2 Peptide, CJC-1295 DAC Peptide, Adipotide Peptide, MGF peptide, PEG-MGF Peptide, and Vilon Peptide.

This version:

• Converts passive sentences to active voice.

• Breaks up long paragraphs for better readability.

• Shortens sentences to below the recommended 25 words on average.

• Retains all key scientific details and study findings.